Celldex Therapeutics (NASDAQ:CLDX) Rating Reiterated by HC Wainwright

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently have a $80.00 price target on the biopharmaceutical company's stock. HC Wainwright's price objective would indicate a potential upside of 89.53% from the stock's current price.

A number of other equities research analysts have also weighed in on CLDX. Guggenheim lifted their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the company a "buy" rating in a report on Tuesday, February 27th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $67.00 price objective on shares of Celldex Therapeutics in a report on Friday, March 22nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $66.00.

Celldex Therapeutics Stock Up 1.3 %

NASDAQ:CLDX traded up $0.56 during trading hours on Tuesday, reaching $42.21. 911,674 shares of the company's stock were exchanged, compared to its average volume of 858,553. The firm has a market capitalization of $2.36 billion, a price-to-earnings ratio of -14.51 and a beta of 1.60. Celldex Therapeutics has a 1-year low of $22.11 and a 1-year high of $53.18. The company has a 50-day moving average of $41.91 and a 200 day moving average of $37.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.76) by $0.19. The firm had revenue of $4.13 million for the quarter, compared to analyst estimates of $1.20 million. Celldex Therapeutics had a negative return on equity of 41.06% and a negative net margin of 2,054.46%. Research analysts forecast that Celldex Therapeutics will post -2.85 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CLDX. Swiss National Bank increased its holdings in Celldex Therapeutics by 17.8% during the 1st quarter. Swiss National Bank now owns 114,300 shares of the biopharmaceutical company's stock valued at $4,797,000 after acquiring an additional 17,300 shares in the last quarter. Jennison Associates LLC raised its position in shares of Celldex Therapeutics by 3,327.0% during the 1st quarter. Jennison Associates LLC now owns 688,080 shares of the biopharmaceutical company's stock worth $28,879,000 after purchasing an additional 668,002 shares during the last quarter. Capstone Investment Advisors LLC lifted its stake in Celldex Therapeutics by 50.7% in the 1st quarter. Capstone Investment Advisors LLC now owns 19,065 shares of the biopharmaceutical company's stock valued at $800,000 after buying an additional 6,412 shares in the last quarter. Principal Financial Group Inc. increased its position in Celldex Therapeutics by 10.0% during the first quarter. Principal Financial Group Inc. now owns 13,153 shares of the biopharmaceutical company's stock worth $552,000 after buying an additional 1,194 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of Celldex Therapeutics in the first quarter valued at $3,816,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.